Stellar Pharmaceuticals Inc. company was founded in 1978 and is based in London, Canada. Stellar Pharmaceuticals Inc. engages in the development and marketing of polysaccharide-based therapeutic products used in the treatment of osteoarthritis and cystitis. It offers NeoVisc, a three injection sodium hyaluronate therapy for the treatment of osteoarthritis; and Uracyst for the treatment of interstitial cystitis, a painful bladder syndrome an inflammatory disease of the urinary bladder wall. The company also has in-licensing agreement for the distribution and sale of BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. Stellar markets its products to medical physicians, pharmacies, hospitals, and patient support groups in Canada through its sales force, as well as out-licenses its products to companies in the United States, Europe, Romania, the Russian Federation, China, Israel, the Middle East, Latin America, the Caribbean, Malaysia, Singapore, and Brunei.

Stiefel Laboratories, Inc. company's products treat a variety of dermatological ailments including acne, psoriasis, and even warts. Among the company's prescribed products are Duac and Brevoxyl acne medications and rosacea treatment Rosac. Stiefel also makes such over-the-counter remedies as fungal infection treatment Zeasorb and Sarna Lotion for itchy skin. Through subsidiaries, the company has manufacturing, marketing, and research operations in more than 30 countries, and markets it products in more than 70 countries. Founded in 1847, the company was owned by the Stiefel family before being acquired by GlaxoSmithKline in 2009.

Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey. Cambrex Corporation, a life sciences company, provides products and services to develop and commercialize active pharmaceutical ingredients and advanced intermediates. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through direct sales and independent agents to pharmaceutical and generic drug companies worldwide.

Synteract, Inc. company has overseen hundreds of projects for clients that include biotechnology and pharmaceutical companies, as well as medical device makers. On top of research services, Synteract offers clients proprietary and customizable software solutions for managing research and trial data. The company's expertise covers a wide range of health issues, including oncology, HIV/AIDS, ophthalmology, and gastrointestinal disorders. Founded in 1995, Synteract maintains offices in San Diego, Philadelphia, and North Carolina.

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

Cellectis SA company develops technologies involving the research and development of rational genome engineering (making changes in the genetics of a cell or organism). The company's research is primarily based on the Meganucleasus, a natural classification of DNA that isolates unique breaks at key locations within living cells. Its patented Meganuclease Recombination Systems technology helps to initiate the rational genome engineering process, which in turn can help treat diseases and augment genetic codes.

CEO Marc Coucke co-founded Omega Pharma NV company in 1987. Omega Pharma's first product was generic shampoo, which it sold to pharmacies. Omega Pharma NV is a Belgium-based provider of healthcare products and services for the pharmacies and other medical sectors. The Company specializes in the development, marketing and sales of health and personal care products, which can be obtained by the end-consumer without medical prescription (over the counter or OTC products). Omega Pharma NV consists of five business units, and is engaged in the provision of consumer-oriented medicines and healthcare products. It is composed of Omega Pharma Belgium, Omega Pharma France, Omega Pharma Northern Europe, Omega Pharma Southern Europe and Omega Pharma Rest of the World. As of December 31, 2008, the Company operated in over 30 countries, including most of the European countries, as well as Australia, New Zealand and Argentina.

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States. The company's lead product candidate includes RDEA594, a product for the treatment of hyperuricemia and gout. Its other products comprise RDEA806 for the treatment of patients with HIV; and RDEA427, a second-generation NNRTI for the treatment of HIV, in a human micro-dose pharmacokinetic study. Ardea Biosciences is evaluating RDEA119, a non-ATP EK inhibitor, in a Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. It also develops RDEA436 for the treatment of inflammation. The company is based in San Diego, California.

Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania. Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The company's proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain.

IRIX Pharmaceuticals develops, tests, and manufactures drugs and drug ingredients for pharmaceutical companies. Services include discovery support, process research and development, clinical supply, manufacturing, and commercial production. It also helps clients work through the regulatory red tape. The company maintains three facilities in South Carolina. Its Florence facility has laboratories devoted to developing and testing new candidates. IRIX was formed in 1996 by CEO Guy Steenrod, former president of Roche Carolina -- the process discovery and development arm of Roche Pharmaceutical -- and a group of South Carolina investors.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.